255 related articles for article (PubMed ID: 37569677)
1. EP300 as a Molecular Integrator of Fibrotic Transcriptional Programs.
Rubio K; Molina-Herrera A; Pérez-González A; Hernández-Galdámez HV; Piña-Vázquez C; Araujo-Ramos T; Singh I
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569677
[TBL] [Abstract][Full Text] [Related]
2. Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.
Williams LM; McCann FE; Cabrita MA; Layton T; Cribbs A; Knezevic B; Fang H; Knight J; Zhang M; Fischer R; Bonham S; Steenbeek LM; Yang N; Sood M; Bainbridge C; Warwick D; Harry L; Davidson D; Xie W; Sundstrӧm M; Feldmann M; Nanchahal J
Proc Natl Acad Sci U S A; 2020 Aug; 117(34):20753-20763. PubMed ID: 32759223
[TBL] [Abstract][Full Text] [Related]
3. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis.
Ghosh AK; Varga J
J Cell Physiol; 2007 Dec; 213(3):663-71. PubMed ID: 17559085
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of EP300 and DDR1 synergistically alleviates pulmonary fibrosis in vitro and in vivo.
Tao J; Zhang M; Wen Z; Wang B; Zhang L; Ou Y; Tang X; Yu X; Jiang Q
Biomed Pharmacother; 2018 Oct; 106():1727-1733. PubMed ID: 30119248
[TBL] [Abstract][Full Text] [Related]
5. A dynamic H3K27ac signature identifies VEGFA-stimulated endothelial enhancers and requires EP300 activity.
Zhang B; Day DS; Ho JW; Song L; Cao J; Christodoulou D; Seidman JG; Crawford GE; Park PJ; Pu WT
Genome Res; 2013 Jun; 23(6):917-27. PubMed ID: 23547170
[TBL] [Abstract][Full Text] [Related]
6. Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor.
Kanada R; Kagoshima Y; Suzuki T; Nakamura A; Funami H; Watanabe J; Asano M; Takahashi M; Ubukata O; Suzuki K; Aikawa T; Sato K; Goto M; Setsu G; Ito K; Kihara K; Kuroha M; Kohno T; Ogiwara H; Isoyama T; Tominaga Y; Higuchi S; Naito H
J Med Chem; 2023 Jan; 66(1):695-715. PubMed ID: 36572866
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
Ghosh S; Taylor A; Chin M; Huang HR; Conery AR; Mertz JA; Salmeron A; Dakle PJ; Mele D; Cote A; Jayaram H; Setser JW; Poy F; Hatzivassiliou G; DeAlmeida-Nagata D; Sandy P; Hatton C; Romero FA; Chiang E; Reimer T; Crawford T; Pardo E; Watson VG; Tsui V; Cochran AG; Zawadzke L; Harmange JC; Audia JE; Bryant BM; Cummings RT; Magnuson SR; Grogan JL; Bellon SF; Albrecht BK; Sims RJ; Lora JM
J Biol Chem; 2016 Jun; 291(25):13014-27. PubMed ID: 27056325
[TBL] [Abstract][Full Text] [Related]
8. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Korzus E
Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
[TBL] [Abstract][Full Text] [Related]
9. Histone acetylation of glucose-induced thioredoxin-interacting protein gene expression in pancreatic islets.
Bompada P; Atac D; Luan C; Andersson R; Omella JD; Laakso EO; Wright J; Groop L; De Marinis Y
Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):82-91. PubMed ID: 27989964
[TBL] [Abstract][Full Text] [Related]
10. H4K16 acetylation marks active genes and enhancers of embryonic stem cells, but does not alter chromatin compaction.
Taylor GC; Eskeland R; Hekimoglu-Balkan B; Pradeepa MM; Bickmore WA
Genome Res; 2013 Dec; 23(12):2053-65. PubMed ID: 23990607
[TBL] [Abstract][Full Text] [Related]
11. Histone Acetyltransferase-Dependent Pathways Mediate Upregulation of NADPH Oxidase 5 in Human Macrophages under Inflammatory Conditions: A Potential Mechanism of Reactive Oxygen Species Overproduction in Atherosclerosis.
Vlad ML; Manea SA; Lazar AG; Raicu M; Muresian H; Simionescu M; Manea A
Oxid Med Cell Longev; 2019; 2019():3201062. PubMed ID: 31565149
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modification of BDNF mediates neuropathic pain via miR-30a-3p/EP300 axis in CCI rats.
Tan M; Shen L; Hou Y
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33103739
[TBL] [Abstract][Full Text] [Related]
13. Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis.
Aseem SO; Jalan-Sakrikar N; Chi C; Navarro-Corcuera A; De Assuncao TM; Hamdan FH; Chowdhury S; Banales JM; Johnsen SA; Shah VH; Huebert RC
Gastroenterology; 2021 Feb; 160(3):889-905.e10. PubMed ID: 33058867
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
[TBL] [Abstract][Full Text] [Related]
15. Histone acetyltransferase inhibitor C646 reverses epithelial to mesenchymal transition of human peritoneal mesothelial cells via blocking TGF-β1/Smad3 signaling pathway in vitro.
Yang Y; Liu K; Liang Y; Chen Y; Chen Y; Gong Y
Int J Clin Exp Pathol; 2015; 8(3):2746-54. PubMed ID: 26045780
[TBL] [Abstract][Full Text] [Related]
16. Assays for Validating Histone Acetyltransferase Inhibitors.
Waddell AR; Liao D
J Vis Exp; 2020 Aug; (162):. PubMed ID: 32831305
[TBL] [Abstract][Full Text] [Related]
17. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
18. Thrombin Induces CCL2 Expression in Human Lung Fibroblasts via p300 Mediated Histone Acetylation and NF-KappaB Activation.
Deng X; Zhou X; Deng Y; Liu F; Feng X; Yin Q; Gu Y; Shi S; Xu M
J Cell Biochem; 2017 Nov; 118(11):4012-4019. PubMed ID: 28407300
[TBL] [Abstract][Full Text] [Related]
19. In silico analysis reveals EP300 as a panCancer inhibitor of anti-tumor immune response via metabolic modulation.
Krupar R; Watermann C; Idel C; Ribbat-Idel J; Offermann A; Pasternack H; Kirfel J; Sikora AG; Perner S
Sci Rep; 2020 Jun; 10(1):9389. PubMed ID: 32523042
[TBL] [Abstract][Full Text] [Related]
20. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
